A groundbreaking new imaging tool has been developed to significantly cut the long wait for an endometriosis diagnosis and potentially spare patients from invasive procedures. The technique uses a molecular tracer called maraciclatide, which is injected into the patient and binds to a specific protein, followed by a SPECT-CT scan to visualise new blood vessel growth and inflammation.
Current Diagnosis Challenges
Currently, the average time for an official endometriosis diagnosis in the UK is approximately nine years and four months, often involving invasive surgical procedures like laparoscopy. This delay can cause significant physical and emotional distress for patients.
Detect Trial Results
The Detect trial found that the new imaging method successfully detected the presence or absence of endometriosis in 84 per cent of participants and provided images of the condition in 14 of 17 confirmed cases. Researchers believe that if these results are replicated in larger studies, maraciclatide could become an extremely valuable tool to reduce diagnostic delays and aid in the development of new treatments.
In full, Oxford University researchers have developed this breakthrough scan that could slash the nine-year wait for an endometriosis diagnosis, offering hope to millions of women affected by the condition.
